TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00362869

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Administered at a dose of 500 mg once a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Administered at a dose of 500 mg once a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Administered at a dose of 500 mg once a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: Administered at a dose of 500 mg once a day for 3 days

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Levofloxacin
Description: Administered at a dose of 500 mg once a day for 3 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Sodium bicarbonate solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sodium bicarbonate solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enteroaggregative E. coli (EAEC)
Description: Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enteroaggregative E. coli (EAEC)
Description: Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enteroaggregative E. coli (EAEC)
Description: Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Enteroaggregative E. coli (EAEC)
Description: Dosages: 1X10\^9, 5X10\^9, 1X10\^10, and 5X10\^10 cfu; given in a sodium bicarbonate solution
Study: NCT03329066

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MAST - Managing Asthma & Sleep in Teens
Description: This behavioral intervention will teach teenagers asthma self-care strategies and sleep hygiene.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: ASMA - Asthma Self-Management for Adol
Description: This behavioral intervention focuses only on asthma care.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Information & Referral Control Group
Description: Students learn basic information about asthma and sleep, as well as other health topics relevant to teenagers.
Study: NCT01833364

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of the Peripheral Nerve Graft
Description: The preparatory surgery for harvesting the peripheral nerve graft will take place in the operating room at the time of the Stage I surgery for the DBS procedure. The nerve exposure and preparation will take approximately 15 minutes of operating time in addition to the DBS procedure which typically takes 75-90 minutes.~The implantation of the nerve graft will take place in the operating room at the end of the second stage surgery for DBS. The graft harvesting and implantation will take approximately 15 minutes in addition to the 4 hours that is needed for the DBS surgery. The subject's peripheral nerve graft will be implanted into the substantia nigra unilaterally. This is a single arm trial to assess safety and feasibility.
Study: NCT02886858

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Device : Transcranial direct current stimulation
Description: The anode will be applied over the F3 area and the cathode over the F4 area. The current dose is 2mA. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Device : sham Transcranial direct current stimulation
Description: The anode will be applied over the F3 area and the cathode over the F4 area. Electrodes will be 7x5cm in size. The investigators will apply 2 daily, tDCS sessions of 30 minutes, weekly the first month, fortnightly the second and third month, monthly the following 3 months.
Study: NCT01872403

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nanoparticle albumin-bound paclitaxel/carboplatin
Description: Neoadjuvant chemotherapy of nanoparticle albumin-bound paclitaxel/carboplatin vs. paclitaxel /carboplatin in stage Ⅱ B and IIIA squamous cell carcinoma of the lung:
Study: NCT01435395

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide, bevacizumab and bortezomib
Description: Escalating temozolomide with standard dose bevacizumab and bortezomib
Study: NCT01801410

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Foley Catheter
Description: Transcervical Foley catheter (silicone, size 18F with 30ml balloon)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Misoprostol
Description: 25mcg every 2 hours for maximum of 12 doses
Study: NCT02368171

Intervention type: OTHER
Intervention: measure exhaled carbon monoxide and nitric oxide
Study: NCT00882206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vorinostat
Description: Days 1-4, (230 mg/m2)orally divided twice a day (max dose 400 mg daily)
Study: NCT03913260

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3375880
Description: Administered SC

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Buffer Matrix (No LY3375880)
Description: Administered SC
Study: NCT03258346

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will consume 8oz of pomegranate juice daily, that has had the polyphenols removed.
Study: NCT03913260

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Description: AI used to administer LY3375880 or Buffer Matrix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Description: AI used to administer LY3375880 or Buffer Matrix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Autoinjector (AI)
Description: AI used to administer LY3375880 or Buffer Matrix

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Autoinjector (AI)
Description: AI used to administer LY3375880 or Buffer Matrix

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Syringe
Description: Manual syringe used to inject LY3375880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Syringe
Description: Manual syringe used to inject LY3375880

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Manual Syringe
Description: Manual syringe used to inject LY3375880
Study: NCT04049916

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pyronaridine Tetraphosphate/Artesunate
Description: Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pyronaridine Tetraphosphate/Artesunate
Description: Adults: Tablets containing 180 mg pyronaridine-tetraphosphate/60mg artesunate (Pyramax, Shin Poong Pharmaceutical Co.), administered according to weight. Children: Granules containing 60 mg pyronaridine-tetraphosphate/20mg artesunate, administered according to weight.
Study: NCT00799422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Clear Care
Description: Commercially marketed contact lens solution for contact lens care

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
Study: NCT01104584

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gadobutrol (Gadavist, Gadovist, BAY86-4875)
Description: A single bolus injection of gadobutrol 1.0 M; 0.1 mmol/kg body weight
Study: NCT04049916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dihydroartemisinin/Piperaquine
Description: Tablets containing 40 mg dihydroartemisinin/320 mg piperaquine tablets (Eurartesim, Sigma Tau), administered according to weight.
Study: NCT02466919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pantoprazole
Description: H. pylori eradication therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pantoprazole
Description: H. pylori eradication therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin
Description: H. pylori eradication therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amoxicillin
Description: H. pylori eradication therapy
Study: NCT04049916

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Primaquine Diphosphate
Description: Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Primaquine Diphosphate
Description: Extemporaneous preparation of 1mg/mL primaquine phosphate solution, from tablets containing 30mg primaquine (A-PQ 30®, ACE pharmaceuticals, NL) dissolved in 30mL water with a non-interacting fruit-flavoured syrup. Solution will be given at 0.25mg/kg.
Study: NCT02868541

Intervention type: OTHER
Intervention: Naso pharyngeal swab
Description: Naso pharyngeal swab
Study: NCT00799422

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Contact lenses
Description: Acuvue Oasys silicone hydrogel contact lenses per participant's habitual prescription worn 8-10 hours per day for one week.
Study: NCT00810173

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: phone call support
Description: The intervention group received a phone call support for 6 weeks to incentive to increase the number of steps/day.
Study: NCT05571267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 2 mg, administered by intravitreal injection
Study: NCT04207021

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Experimental: Curcumin derivate
Description: two capsules per day, one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: two capsules per day (containing no bioactive compound, only hydroxypropyl methylcellulose, gellan gum, pigment), one capsule to be taken before breakfast and one before dinner for a period of 6 weeks.
Study: NCT05571267

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 2 mg, administered by intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zimura
Description: Zimura 2 mg, administered by intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Avastin
Description: Avastin 1.25 mg, administered by intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lucentis
Description: Lucentis 0.5 mg, administered by intravitreal injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eylea
Description: Eylea 2 mg, administered by intravitreal injection
Study: NCT02591212

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Green Dot
Description: Green Dot bystander intervention program (www.livethegreendot.com) seeks to empower potential bystanders (students) to actively engage their peers in violence prevention. Intensive bystander training involves interactive, skill development with role-play of bystander behaviors. This program focuses on building knowledge and skills related to interpersonal violence and being an active bystander. There is a structured curriculum for both introductory sessions and longer, skill-building sessions.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Wellness Initiatives for Student Empowerment
Description: Wellness training to be provided in modules by Student Wellness ambassadors (http://www.uky.edu/wise). The Student Wellness Ambassadors mission is to inform students on aspects of wellness such as alcohol, drugs, mental health, general well-being, and financial wellness in orer to promote safe and responsible lifestyle decisions. Intervention will address elements of student wellness including campus resources for health issues, AOD abuse prevention/harm reduction strategies, time management and study tips, stress management and reduction, and healthy coping strategies. Training may also provide information on academic resources, money management, and other elements of healthy adaptation to college life.
Study: NCT03574311

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ferric carboxymaltose
Description: A single dose of drug or placebo is administered preoperatively to participants

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Physiological saline
Description: Single infusion 100 ml physiological saline infusion preoperatively
Study: NCT01699529

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Medtronic Multi-electrode Radiofrequency (RF) Renal Denervation system
Description: The Medtronic Multi-electrode Radiofrequency Renal Denervation System is comprised of a single-use, disposable catheter and a reusable generator.
Study: NCT01246362

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Given placebo

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoricoxib
Description: Given etoricoxib 120mg 24 hours preoperatively and 120mg 2 hours preoperatively
Study: NCT03476317

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vancomycin
Description: Oral suspension 4 times daily (Day 1-14)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vancomycin
Description: Oral suspension 4 times daily (Day 1-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neomycin
Description: Oral three times daily (Days 1-3)
Study: NCT02466919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metronidazole
Description: H. pylori eradication therapy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metronidazole
Description: H. pylori eradication therapy

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levofloxacin
Description: H. pylori eradication therapy
Study: NCT03476317

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Neomycin
Description: Oral three times daily (Days 1-3)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin
Description: Oral twice daily (Days 4-14)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ciprofloxacin
Description: Oral twice daily (Days 4-14)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol 3350
Description: Dissolved in Gatorade on day 2

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Polyethylene Glycol 3350
Description: Dissolved in Gatorade on day 2

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fluconazole
Description: Orally once daily (Day 1-14)
Study: NCT04553224

Intervention type: OTHER
Group type: OTHER
Intervention: Clinical evaluations
Description: SCORAD and target SCORAD

Intervention type: OTHER
Group type: OTHER
Intervention: Non-invasive instrumental measurements
Description: TEWL, cutaneous hydration, skin lipidic analysis, colorimetry, hydration index

Intervention type: OTHER
Group type: OTHER
Intervention: Subject's evaluations
Description: PO-SCORAD, target PO-SCORAD and subject's questionnaire
Study: NCT03417791

Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study: NCT00353652

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study#1: chlorthalidone (CTD), titrated dose
Description: Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Study#1: chlorthalidone (CTD), titrated dose
Description: Participants in study #1 will receive 3 months of chlorthalidone (12.5-25 mg/d) at the dose titrated to achieve 24-h ambulatory BP \< 130/80 mmHg
Study: NCT02466919

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clarithromycin
Description: H. pylori eradication therapy
Study: NCT04165837

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FB-101
Description: Part A - Single Ascending Dose study Part B - Multiple Ascending Dose study

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Part A - Single Ascending Dose matching placebo study Part B - Multiple Ascending Dose matching placebo study
Study: NCT03212729

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: ANTIMICROBIAL PHOTODYNAMIC THERAPY
Description: The aPDT was performed with 0.01% methylene blue and irradiated with low-level laser therapy (InGaAIP, 660 nm; 100 mW; 40 sec) with an optical fiber-coupled. Another irradiation (3 J; 30 sec; spot size of 3 mm2) was performed in the gingiva close to the apical foramen.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional endodontic treatment
Description: After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Conventional endodontic treatment
Description: After local anesthesia the supragingival calculus, biofilm and the carious tissues were removed. The access cavity preparation was completed. The crown-down technique was performed using Gates Glidden and Kerr files with an anatomic diameter compatible to the radicular canal, and the irrigation was performed with 5 mL of 2.5% NaOCl solution between each endodontic file. The working length was established 1 mm short of the radiographic apex. Smear layer was removed by rinsing the canal with 17% ethylene diamine tetra-acetic acid solution, which was left in the canal for 5 min, followed by a final irrigation with 15 mL of 2.5% NaOCl solution. Calcium hydroxide paste with paramonoclorophenol, was inserted into the canal, filling the root canal as temporary medication between the sessions. The coronal sealing was performed using Coltosol, followed by glass ionomer Maxxion R. Seven days later the root canal was filled by the hybrid Tagger technique, with a Mc Spadden condenser.
Study: NCT03260712

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: The dose of pembrolizumab in this trial is 200 mg Q3W.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 25mg/m2 cisplatin on days 1 and 8 of a 21 day cycle

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000mg/m2 gemcitabine on days 1 and 8 of a 21 day cycle
Study: NCT00138684

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: venesection
Description: Venesection therapy is realised every 7 - 14 days until iron desaturation completion.